Please ensure Javascript is enabled for purposes of website accessibility
Max Macaluso

Max Macaluso

TMFMassimo

Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Recent articles

Abbott's Earnings Made Easy

What were the takeaways from Abbott's third-quarter results?


The Bear and Bull Cases for Amarin

Why are some investors bearish and others bullish on this controversial biotech stock?


Down 20%: Ariad Pharmaceuticals' Second Dose of Bad News

Shares of Ariad plunged 70% earlier this week -- why did the shares drop another 20% today?


The Government Shutdown Won't Stop This FDA Meeting

Amarin's triglyceride-lowering drug Vascepa competes with GlaxoSmithKline's Lovaza and may also go head-to-head with AstraZeneca's Epanova next year, but Vascepa's FDA advisory committee meeting in October is far more important to investors.


Can This Obesity-Drug Maker Beat Arena and VIVUS in Europe?

Arena and VIVUS have been failed to get their drugs on the market in the EU, but can Orexigen jump over the regulatory hurdle and beat them to market?

Omeros Corporation's Eye-Popping Surge

Why are shares of biotech company Omeros jumping today?


2 Stocks to Watch as Obamacare Exchanges Roll Out

Two stocks soaring from Obamacare.


Is Pfizer's Oncology Division Poised to Grow?

A deep dive into Pfizer's oncology portfolio and pipeline.


Time to Panic About Merck's Patent Expirations?

A look at which products Merck will lose patent protection on in the coming years.


AbbVie's 3 Biggest Opportunities

What are the three opportunities that AbbVie investors need to watch? (Companies discussed in this video are ABBV and GILD.)

3 Dividends Investors Love

Sanofi, Bristol-Myers Squibb, and Teva are three health-care stocks that The Motley Fool CAPS players rate highly, but are they all well positioned?


3 Reasons Behind Rite Aid's Incredible Run

Retail pharmacies like CVS and Walgreen have performed well so far this year, but why is Rite Aid up a surprising 250%?


Should Merck Copy Pfizer and Join the "Spinoff Club"?

Pfizer spun out its animal health unit, Zoetis, in 2013. Should Merck do the same?


What Was Behind Pacific Biosciences' 70% Pop?

The details behind Roche's deal with Pacific Biosciences of California.


The Details Behind MAKO Surgical's 80% Pop

The acquisition that boosted MAKO's share price today.

Market Checkup: Sept. 25

Today's health-care headlines.


3 Reasons to Sell Bristol-Myers Squibb

Are there any reasons to sell one of the best performing pharmaceutical stocks of the year?


Stryker's Shocking Move for Mako Surgical

Stryker's $1.65 billion offer to buy struggling robotic surgery company Mako takes the market by surprise.


3 Catalysts Bristol-Myers Squibb Investors Need to Watch

What are the key events that Bristol-Myers Squibb investors need to watch in the coming months?


Can Merck Recover From This FDA Rejection?

Merck's latest setback comes from the Food and Drug Administration's rejection of sugammadex.